

1 **Type of article:** Systematic review article

2 **Title of the article: Clinical Virology and Effect of Vaccination and Monoclonal Antibodies**
3 **against SARS-CoV-2 Omicron Sub Variant BF.7 (BA.5.2.1.7) : A systematic review.**

4 **Name of the Authors:** Santenna Chenchula*¹, Krishna Chaitanya Amarneni, Mohan Krishna
5 Ghanta, Padmavathi R², Madhu Bhargavi Chandra, Madhu Babu Adusumilli , Madhavrao
6 Chavan¹, Sofia Mudda, Rupesh Gupta, Bhawna Lakhawat.

7 **Running Title: The BF.7 (BA.5.2.1.7) variant Virology and Preventing Strategies.**

8 **The affiliation(s) of the author(s):**

- 9 1. *Santenna Chenchula, PhD, Department of Pharmacology, All India Institute of
10 Medical Sciences (AIIMS)Bhopal, Madhya Pradesh, India. Email: csanten7@gmail.com
- 11 2. Krishna Chaitanya Amarneni, Faculty, Western Michigan University, Kalamazoo,
12 Michigan. Email: krishnachaitanya.amarneni@med.wmich.edu
- 13 3. Mohan Krishna Ghanta, Assistant Professor, Department of Pharmacology, MVJ
14 Medical College and Research Hospital, Bangalore, Karnataka, Email:
15 mohanakrishna.ghanta@gmail.com
- 16 4. Padmavathi R, Resident, SVS Medical College and Hospital, Telangana, India. Email:
17 pad.mythili@gmail.com
- 18 5. Madhu Bhargavi Chandra, Intern, All India Institute of Medical sciences, Bhopal.
19 email: madhubhargavi196@gmail.com
- 20 6. Madhu Babu Adusumilli, Intern, All India Institute of Medical sciences, Bhopal. email:
21 madhu.adusumilli3@gmail.com
- 22 7. Sofia Mudda, Medical Officer, All India Institute of Medical sciences, Bhopal. Email:
23 sophia.dr@gmail.com

- 24 8. Madhavrao Chavan, Department of Pharmacology, All India Institute of Medical
25 Sciences (AIIMS) Mangalagiri, Andhra Pradesh, India. Email:
26 madhavrao.pharm@aiismangalagiri.edu.in
- 27 9. Rupesh Gupta, Assistant Professor, Department of Internal Medicine, Government
28 Medical College, Shahdol, Madhyapradesh, India. Email: neolog.raj@gmail.com
- 29 10. Bhawna Lakhawat , Tutor, department of Pharmacology, All India Institute of Medical
30 sciences, Bhopal, Email: bhawnaajmer001@gmail.com

31 ***Corresponding Author:** Santenna Chenchula, Department of Pharmacology, 3rd floor, All
32 India Institute of Medical Sciences, Bhopal,462020, Madhya Pradesh, India.

33 **Phone no:** 7987220348

34 **Email Id:** csanten7@gmail.com.

35 **The total number of pages:**10.

36 **Total number of Tables/Graphs:**0

37 **Total number of Images:** 0

38 **Word counts: For abstract:** 187

39 **For the text:** 2133

40 Prior publication: Nil

41 Sources of Support: Nil

42 Conflicts of interest: Nil

43 Read and approved by all authors: Yes.

44

45

46

47

48 **Abstract:**

49 Since its identification in late 2019 the novel coronavirus, severe acute respiratory syndrome
50 coronavirus 2 (SARS-CoV-2) In Wuhan, China, by the World Health Organization (WHO),
51 which cause the coronavirus disease 2019, it is rapidly spreading, resulting in the global
52 pandemic. As of 19 December 2022, more than 64 million confirmed cases and 6,645,812 deaths
53 have been reported across the world. Over time, the SARS-CoV-2 acquired genetic
54 mutations resulting in multiple types of SARS-CoV-2 variants and subvariants that have been
55 confirmed. The Omicron (B.1.1.529) variant was identified later in November 2021, with
56 enhanced immune escape and was followed with various sublineages due to mutations in the
57 spike protein of the SARS-CoV-2. However, rapid resurge in COVID-19 reports by Omicron
58 subvariant BF.7(BA.2.75.2) in China and other countries, alarming global threat. The present
59 systematic review was conducted using "Omicron" AND "BA.5.2.1.7" OR "BF.7" in Pub Med,
60 Google Scholar and MedRXiv database and grey literature from the authentic database and
61 websites . We have identified a total of 14 published studies. We have reviewed all the eligible
62 available studies to understand the viral mutations, factors associated with increase in the reports
63 of COVID-19 cases in china and across the world and to evaluate the effectiveness of
64 vaccination and monoclonal antibodies against BF.7 variant.

65

66

67

68

Text File

69 **Introduction:**

70

71 Since its identification in late 2019 the novel coronavirus, severe acute respiratory syndrome
72 coronavirus 2 (SARS-CoV-2) In Wuhan, China, by the World Health Organization (WHO),
73 which cause the coronavirus disease 2019, it is rapidly spreading, resulting in the global
74 pandemic [1]. As of 19 December 2022, . As of 19 December 2022, more than 64 million
75 confirmed cases and 6,645,812 deaths have been reported across the world [2]. Over time, the
76 SARS-CoV-2 acquired genetic mutations resulting in multiple types of SARS-CoV-2 variants
77 and subvariants that have been confirmed [3]. Certain variants have gained keen attention
78 because of their characteristics of rapid transmissibility, enhanced immune escape and severity
79 of the infection and these are considered variants of concern (VOC) that continue to threaten
80 public health [3].

81 Later in November 2021, the Omicron (B.1.1.529) variant with enhanced immune escape was
82 first reported from Botswana and thereafter from South Africa with an increased infection [3-4].
83 Very soon it has been spread swiftly to several other countries, across the world with subtle raise
84 in the number of COVID-19 infections [4-5]. Subsequently, Omicron sublineages with
85 increasingly greater replication advantages emerged, replacing the previous predominant
86 sublineage [3]. There are about 200 sublineages of Omicron [3]. The original Omicron variant
87 was sublineage BA.1, BA.2, BA.3, BA.4 and BA.5 [5-6]. Other Omicron sublineages, such as
88 BQ.1, BQ.11, BF.7, BA.2.75, and XBB, which evolved from various previously circulating
89 sublineages, have been increasing in prevalence worldwide [7]. Each sublineage differs from the
90 others by several mutations in the spike protein except for BA.4 and BA.5, which have identical
91 spike proteins [8]. Evidence has shown that, all omicron sub-variants are distinct from pre-
92 omicron variants, including BA.1, BA.2 and BA.5 omicron sub-variants are also antigenically
93 distinct from each other [9].

94 In response to the current surge in the COVID-19 reports by Omicron subvariant BF.7 also
95 known as BA.2.75.2 in China and other countries, triggering global alarm the present review was
96 conducted to understand the virology, factors associated with increased reports of COVID-19
97 infections with BF.7 variant in China and possible urgent preventing strategies to be taken to
98 curtail the novel omicron variants outbreak across the world.

99

100 **Methodology:**

101 We have performed a comprehensive literature search was performed from inception to till
102 January 2022, using the MeSH terms and keywords "Omicron" AND "BA.5.2.1.7" OR "BF.7" in
103 Pub Med, Google Scholar and MedRXiv database and grey literature from the authentic database
104 and websites to find relative information about Omicron subvariant BF.7 (BA.5.2.1.7) and data
105 assessed to understand viral mutations, factors associated with increased reports of COVID-19
106 infections with BF.7 variant in china and on literature evidence on vaccine effectiveness and
107 monoclonalantibodies against BF.7 to understand possible urgent preventing strategies to be
108 taken to curtail the novel omicron variants outbreak in china and across the world.

109

110 **Results:**

111 In the present review, after removing duplications and literature not mentioned regarding BF.7 or
112 BA.5.2.1.7, a total of 14 studies were found eligible among the 79 studies . The SARS-CoV-2
113 Omicron BF.7 (BA.5.2.1.7) a subvariant of BA.5, is responsible for the ongoing resurgence of
114 cases since late September 2022 in China [10].To date, BF.7 (BA.5.2.1.7) subvariant has been

115 reported in Belgium, China, Denmark, Norway, France, Germany, India, Mongolia, the United
116 Kingdom and the United States[11-12]. However, Before China, the BF.7 variant has been
117 circulating at an incredibly intense level in USA and Europe since August 2022[8-10]. The
118 current reports from China indicate BF.7 has the strongest infection ability out of the Omicron
119 subvariants, being quicker to transmit than other variants, having a shorter incubation period, and
120 with a greater capacity to infect people who have had a previous COVID infection, or been
121 vaccinated, or both [11].

122 The most symptoms of an infection with BF.7 were similar to those associated with other
123 Omicron subvariants, primarily upper respiratory symptoms[12].Patients may have a fever,
124 cough, sore throat, running nose and fatigue, among other symptoms and gastrointestinal
125 symptoms like vomiting and diarrhoea [11-12]. The basic reproduction number R_t of omicron
126 BF.7(BA.5.2.1.7) variant was 10 to 18.6. which is significantly high compared to BA.1 Omicron
127 variant which is only 5.08[11].A study by Kathy Leung et al., in china during November to
128 December 2022 found that , the R_t increased to 3.42 (95% CrI: 2.79 – 4.17) on November 18,
129 Infection incidence peaked on December 10, and the cumulative infection attack rate was 42.5%
130 (95% CrI: 20.3 – 63.9) on December 14[13]. The high transmission rate of BF.7(BA.5.2.1.7), is
131 due to the novel mutations in the spike protein [11-15]. Evidence from the Molecular modelling
132 revealed the mechanisms of antibody-mediated immune evasion by R346T, K444T, F486S, and
133 D1199N mutations on the receptor-binding domain [15]. However, the omicron variant BF.7
134 carries an additional specific mutation, R346T in the spike protein of SARS-CoV-2 which is
135 derived from the BA.4/5 subvariant, which is why the BF.7 variant has a 4.4-fold higher
136 neutralization resistance than the original D614G variant [15]. The Arg346 mutations R346T in
137 the BF.7 variant spike glycoprotein, particularly those on the receptor-binding domain has been

138 associated with an increased immune escape capability to neutralize antibodies generated by
139 vaccines or previous infection[11-15].Therefore, COVID-19 infection with BF.7 variant may
140 cause a serious illness in populations with weaker immune systems such as the elderly and those
141 with concomitant comorbidities [13-15]. A study by Wang, Qian et al., investigated the
142 sensitivity profile of omicron subvariants to neutralisation by a panel of 23 mAbs found that, all
143 mAbs retained potency against earlier omicron subvariants, including that targeted different
144 epitope clusters of the receptor-binding domain (RBD) of the viral spike and others that target
145 non-RBD epitopes [16]. The neutralisation profiles of BF.7 did not differ much from that of
146 BA.4/5 except those mAbs in RBD class 3 which showed substantial reduction in their
147 neutralisation potency against the new subvariants [16]. The reduced neutralizing activity was
148 mainly due to mutation R346T, R346S, or R346I, which are associated with eliminated or
149 weakened hydrogen bonds or salt bridges, or both, between R346 and some RBD class 3 mAbs.
150 In addition, the combination of a monoclonal antibodies cilgavimab and tixagevimab, which had
151 received an emergency use authorisation for the prevention of COVID-19, could also not
152 neutralized BF.7 and other variants such as, BA.4.6, BA.4.7, and BA.5.9[16].

153 **Discussion:**

154 Being quicker to transmit than other Omicron variants, having a shorter incubation period,
155 increased evasion of antibodies and with greater capacity to infect people who have had a
156 previous COVID-19 infection, and/or been vaccinated, or both, the BF.7 variant is causing a
157 significant increase in number COVI-19 cases in China and across the world [16-17]. A SARS-
158 CoV-2 transmission model study by Kathy Leung et al., from China, using the data from recent
159 outbreaks in Hong Kong and Shanghai to compare different scenarios in China concluded that
160 the hospitals will be overwhelmed if infections rise as rapidly because of the easing of Zero

161 COVID policy restrictions and will probably result in about one million deaths over the next few
162 months, the study forecasts [17]. The study also suggests that, if 85% of the population gets a
163 booster fourth dose of the COVID -19 vaccine other than the inactivated-virus vaccines, it could
164 slow the rise in infections and reduce the number of severe infections and deaths by up to 35%
165 [17]. According to this study, if China lifts the zero-COVID policy the Omicron could infect
166 between 160 million and 280 million people and 1.55 million deaths largely among
167 unvaccinated older adults [17]. The study also suggests that, if 85% of the population gets the
168 fourth dose of a vaccine other than the inactivated-virus vaccine could slow the increase in
169 infections, the number of severe infections and deaths [17]. According to reports from China,
170 more than 90% of the population has been fully vaccinated [18]. However, less than half of
171 people aged 80 and over have received three doses of the vaccine [18]. Evidence also shown that,
172 the inactivated vaccine CoronaVac from China produced lower levels of neutralizing antibodies
173 and these antibody levels also dropped quickly over time [18]. In addition, studies also have
174 shown that protection from severe disease was also very less in preventing severe disease and
175 death among 80 years and older [17].

176 Evidence from the literature suggests that booster vaccination is associated with a significant
177 impact on emerging Omicron variants across the world. A study by Sullivan, David J et al., to
178 evaluate polyclonal antibodies from individuals both with at least 3 vaccine doses and also
179 recently recovered from Omicron COVID-19 (VaxCCP) neutralizing activity against new
180 Omicron lineages in 740 individual patient samples from 37 separate cohorts defined by boosted
181 vaccinations with or without recent Omicron COVID-19, as well as infection without
182 vaccination found that more than 96% of the plasma samples from individuals in the recently i.e.,
183 within 6 months boosted VaxCCP study cohorts neutralized BQ.1.1 with 79%, XBB.1 with 22%

184 and BF.7 with 94% variants respectively [19]. Another study by Sullivan DJ et al., on found
185 that, the BA.5-bivalent booster dose vaccines elicited better neutralization against the newly
186 emerged Omicron sublineages including BF.7 variant than the parental mRNA vaccine and those
187 individuals with SARS-CoV-2 infection history develop higher and broader neutralization
188 antibodies against the ongoing novel Omicron sublineages after the BA.5-bivalent booster [20].
189 Another study by Zhu, Ka-Li Jiang et al., found that, two-dose CoronaVac or a third-dose
190 ZF2001 booster elicits limited neutralization against Omicron subvariants 6 months after
191 vaccination but hybrid immunity as well as Delta, BA.1, and BA.2 breakthrough infections
192 induced long-term persistence of the antibody response, and over 70% of sera neutralized BF.7.
193 as well as BA.1, BA.2, BA.4/BA.5[21]. Another systematic review of effect of booster dose
194 vaccination, with 27 studies by Chenchula S et al., found that, booster-dose vaccine efficacy
195 against SARS-CoV-2 variants, including Omicron sublineages [22].

196 **Conclusion:**

197 The present review focusing on the variant of concern Omicron BF.7 with enhanced infectivity
198 and transmissibility potential suggests that in addition to regular surveillance activities, the
199 protection strategies need to rapidly achieve by global vaccination to nonvaccinated populations
200 and booster dose vaccination with other than inactivated vaccines, especially among
201 immunocompromised and vulnerable populations those aged 60 years more and in children, to
202 prevent possible outbreaks of novel SARS-CoV-2 Omicron subvariants and to decrease severity
203 and mortality to mitigate the healthcare and economic impacts due to the emerging Omicron
204 sublineages and future VOCs.

205 **Acknowledgment:**

206 None to declare.

207 **Conflict of Interests:** The authors declare that there are no conflicts of interests.

208 **Grants and funding:** None.

209 **Author Contributions:** Santenna Chenchula conducted the literature search and data extraction
210 and drafted the manuscript. Krishna Chaitanya Amarneni, Mohan Krishna Ghanta, Padmavathi
211 R, Madhu Bhargavi Chandra, Madhu Babu Adusumilli, Bhawna Lakhawat, Madhavrao Chavan,
212 Sofia Mudda, Rupesh Gupta revised the final manuscript. All authors reviewed and approved the
213 final version of the manuscript.

214 **Data Availability:**

215 The data used in this systematic review is available from the corresponding author with a
216 reasonable request.

217 **References:**

218

- 219 1. WHO Coronavirus (COVID-19) dashboard. <https://covid19.who.int/>. Accessed: 20
220 December 2022.
- 221 2. WHO Classification of omicron (B.1.1.529): SARS-CoV-2 variant of concern. Statement 26
222 November, 2021. Accessed: 20 December, 2022: [https://www.who.int/news/item/26-11-
223 2021-classification-of-omicron-\(b.1.1.529\)-sars-cov-2-variant-of-concern](https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern).

- 224 3. Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern. Available from:
225 [https://www.who.int/news/item/26-11-2021-classification-of-omicron-\(b.1.1.529\)-sars-cov-](https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-)
226 [2-variant-of-concern](https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern). Accessed on: 20 December 2022.
- 227 4. Viana R, Moyo S, Amoako DG, et al. Rapid epidemic expansion of the SARS-CoV-2
228 Omicron variant in southern Africa. *Nature*. 2022;603(7902):679-686.
- 229 5. Arora P, Zhang L, Rocha C, et al. Comparable neutralisation evasion of SARS-CoV-2
230 omicron subvariants BA.1, BA.2, and BA.3. *Lancet Infect Dis*. 2022;22(6):766-767.
- 231 6. Rössler A, Netzl A, Knabl L, Schäfer H, Wilks SH, Bante D, et al . BA.2 and BA.5 omicron
232 differ immunologically from both BA.1 omicron and pre-omicron variants. *Nat Commun*.
233 2022 Dec 13;13(1):7701. doi: 10.1038/s41467-022-35312-3.
- 234 7. Implications of the emergence and spread of the SARS-CoV-2 variants of concern BA.4 and
235 BA.5 for the EU/EEA. European Centre for Disease Prevention and Control. Available at:
236 [https://www.ecdc.europa.eu/en/news-events/implications-emergence-spread-sars-cov-2-](https://www.ecdc.europa.eu/en/news-events/implications-emergence-spread-sars-cov-2-variants-concern-ba4-and-ba5)
237 [variants-concern-ba4-and-ba5](https://www.ecdc.europa.eu/en/news-events/implications-emergence-spread-sars-cov-2-variants-concern-ba4-and-ba5) . Accessed on 20 December, 2022.
- 238 8. Tegally H, Moir M, Everatt J, Giovanetti M, Scheepers C, Wilkinson E et al., Emergence of
239 SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa. *Nat Med*. 2022;28(9):1785.
- 240 9. Jian F, Yu Y, Song W, Yisimayi A, Yu L, Gao Y, et al. Further humoral immunity evasion of
241 emerging SARS-CoV-2 BA.4 and BA.5 subvariants. *Lancet Infect Dis*. 2022
242 Nov;22(11):1535-1537. doi: 10.1016/S1473-3099(22)00642-9.
- 243 10. Mallapaty S. Can China avoid a wave of deaths if it lifts strict zero COVID policy? *Nature*.
244 2022 ;612(7939):203. doi: 10.1038/d41586-022-04235-w.

- 245 11. BF.7: What to know about the Omicron COVID variant. Available at :
246 <https://www.cbsnews.com/news/bf7-new-omicron-coronavirus-variant-covid/>. Accessed on
247 20 December 2022.
- 248 12. Aleem A, Akbar Samad AB, Slenker AK. Emerging Variants of SARS-CoV-2 And Novel
249 Therapeutics Against Coronavirus (COVID-19). 2022 Oct 10. In: StatPearls [Internet].
250 Treasure Island (FL): StatPearls Publishing; 2022 Jan-. PMID: 34033342.
- 251 13. Kathy Leung, Eric H. Y. Lau, Carlos K. H. Wong, Gabriel M. Leung, Joseph T. Wu.
252 Estimating the transmission dynamics of Omicron in Beijing, November to December
253 2022. medRxiv 2022.12.15.22283522; doi: <https://doi.org/10.1101/2022.12.15.22283522>.
- 254 14. SARS-CoV-2 Omicron BF.7 variant. Available at : [https://en.wikipedia.org/wiki/SARS-](https://en.wikipedia.org/wiki/SARS-CoV-2_Omicron_BF.7_variant)
255 [CoV-2_Omicron_BF.7_variant](https://en.wikipedia.org/wiki/SARS-CoV-2_Omicron_BF.7_variant). Accessed on 20 December 2022.
- 256 15. Qu P, Evans JP, Faraone JN, Zheng YM, Carlin C, Anghelina M, et al. Enhanced
257 neutralization resistance of SARS-CoV-2 Omicron subvariants BQ.1, BQ.1.1, BA.4.6, BF.7,
258 and BA.2.75.2. *Cell Host Microbe*. 2022 Nov 22;S1931-3128(22)00568-6. doi:
259 10.1016/j.chom.2022.11.012.
- 260 16. Wang Q, Li Z, Ho J, Guo Y, Yeh AY, Mohri H, Liu M, Wang M, Yu J, Shah JG, Chang JY,
261 Herbas F, Yin MT, Sobieszczyk ME, Sheng Z, Liu L, Ho DD. Resistance of SARS-CoV-2
262 omicron subvariant BA.4.6 to antibody neutralisation. *Lancet Infect Dis*. 2022
263 Dec;22(12):1666-1668. doi: 10.1016/S1473-3099(22)00694-6.
- 264 17. Cai J, Deng X, Yang J, Sun K, Liu H, Chen Z, et al . Modeling transmission of SARS-CoV-2
265 Omicron in China. *Nat Med*. 2022 Jul;28(7):1468-1475. doi: 10.1038/s41591-022-01855-7.
- 266 18. China Covid: What is China's policy and how many cases are there?. BBC: Reality check.
267 Available from: <https://www.bbc.com/news/59882774>. Accessed on 20 December 2022.

- 268 19. Mallapaty S. China's COVID vaccines have been crucial - now immunity is waning. *Nature*.
269 2021 Oct;598(7881):398-399. doi: 10.1038/d41586-021-02796-w.
- 270 20. Sullivan DJ, Franchini M, Senefeld JW, Joyner MJ, Casadevall A, Focosi D. Plasma after
271 both SARS-CoV-2 boosted vaccination and COVID-19 potentially neutralizes BQ.1.1 and
272 XBB.1. *bioRxiv* [Preprint]. 2022 Nov 30:2022.11.25.517977. doi:
273 10.1101/2022.11.25.517977.
- 274 21. Zhu, Ka-Li Jiang, Xiao-Lin Wang, Xue-Jun Xia, Xian Zhan, Bing-Dong Cao, Guo-Ping
275 Wang, et al., Durability of Neutralization Against Omicron Subvariants after Vaccination
276 and Breakthrough Infection. Available at
277 SSRN: <https://ssrn.com/abstract=4281072> or <http://dx.doi.org/10.2139/ssrn.4281072>
- 278 22. Chenchula S, Karunakaran P, Sharma S, Chavan M. Current evidence on efficacy of
279 COVID-19 booster dose vaccination against the Omicron variant: A systematic review. *J*
280 *Med Virol*. 2022 ;94(7):2969-2976. doi: 10.1002/jmv.27697.

281

282

283

284

Figure 1: PRISMA Flow Diagram for the study selection.

Identification of studies via in Pub Med, Google Scholar and MedRXiv by Using Following MESH or Key words

"Omicron" AND "BA.5.2.1.7" OR "BF.7"

